Essential Partners
TNXP icon

Essential Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Essential Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.75K Sell
693
-409
-37% -$4.83K ﹤0.01% 1371
2026
Q2 		$14.1K Buy
1,102
+596
+118% +$7.69K 0.01% 1055
2026
Q1 		$6.96K Buy
+506
New +$7.79K ﹤0.01% 1420

Other funds holding TNXP

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Acorn Wealth Advisors
Acorn Wealth Advisors Grand Blanc, Michigan $407M AUM 14.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
CNBT
Cornerstone National Bank & Trust Palatine, Illinois $309M AUM 7.69% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners's TNXP Position: Q3 2026 in Review

Essential Partners reduced its Tonix Pharmaceuticals (TNXP) stake by 37% in Q3 2026, selling an estimated $4.83K and leaving 693 shares worth $6.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Essential Partners first reported a position in TNXP in Q1 2026 and has held it in 3 quarters since. The position peaked at $14.1K in Q2 2026. 16 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

  • Essential Partners held 693 shares of Tonix Pharmaceuticals worth $6.75K as of Q3 2026.
  • Essential Partners sold 409 Tonix Pharmaceuticals shares in Q3 2026, an estimated $4.83K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1371 holding.
  • Essential Partners first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Essential Partners's Tonix Pharmaceuticals position peaked at $14.1K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.